Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

• Melinda J. Gooderham, MSc, MD, FRCPC,
• Chia-Yu Chu, MD, PhD,
• Ricardo Rojo, MD,
• Hernan Valdez, MD,
• Pinaki Biswas, PhD,
• Michael C. Cameron, MD,
• Claire Feeney, MD, PhD,
• Gerardo A. Encinas, MD, MHS,
• Kathleen Peeples-Lamirande, PharmD, MPH,
• Joseph C. Cappelleri, PhD,
• Daniela E. Myers, MPH,
• Marco DiBonaventura, PhD

Affiliations

Melinda J. Gooderham, MSc, MD, FRCPC

SKiN Centre for Dermatology, Peterborough, Ontario, Canada

Chia-Yu Chu, MD, PhD

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

Ricardo Rojo, MD

Pfizer Inc, Groton, Connecticut

Hernan Valdez, MD

Pfizer Inc, New York, New York

Pinaki Biswas, PhD

Pfizer Inc, New York, New York

Michael C. Cameron, MD

Pfizer Inc, New York, New York

Claire Feeney, MD, PhD

Pfizer Ltd, Surrey, United Kingdom

Gerardo A. Encinas, MD, MHS

Pfizer Inc, Vancouver, Canada

Kathleen Peeples-Lamirande, PharmD, MPH

Pfizer Inc, Collegeville, Pennsylvania

Joseph C. Cappelleri, PhD

Pfizer Inc, Groton, Connecticut

Daniela E. Myers, MPH

Pfizer Inc, Collegeville, Pennsylvania

Marco DiBonaventura, PhD

Pfizer Inc, New York, New York; Correspondence to: Marco DiBonaventura, PhD, 235 East 42nd Street, New York, NY 10017